Ipamorelin

Overview

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered one of the mildest GHRPs with fewer side effects than alternatives like GHRP-6.

Mechanism of Action

Ipamorelin mimics ghrelin and binds to the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. Unlike other GHRPs, it does not significantly increase cortisol or prolactin levels, making it more selective in its growth hormone release.

Research Summary

Clinical studies have demonstrated its ability to increase GH release in a dose-dependent manner. It has been studied in post-surgical recovery and bone health contexts. It is frequently combined with CJC-1295 for synergistic GH elevation.

Dosing Information

Reported Side Effects

• Headache
• Water retention
• Tingling or numbness in extremities
• Increased hunger

Research References

• Ipamorelin, the first selective growth hormone secretagogue (1998)
• Safety and efficacy of ipamorelin in growth hormone deficiency (2011)
• Growth hormone secretagogues: history, mechanism of action, and clinical development (1999)